Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

Core Viewpoint - Outlook Therapeutics, Inc. has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development to enhance its strategic initiatives and shareholder value during a critical phase of the company's evolution [3][4]. Company Overview - Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing ONS-5010/LYTENAVA™ (bevacizumab-vikg) to improve the standard of care for retinal diseases [6]. - LYTENAVA™ is the first ophthalmic formulation of bevacizumab to receive marketing authorization from the European Commission and MHRA for treating wet AMD, with a commercial launch already commenced in Germany and the UK [6]. Leadership Appointment - Laura Cantrell brings over 20 years of experience in global corporate strategy, business development, and portfolio leadership within the biotechnology and pharmaceutical sectors [4][5]. - Cantrell has held senior roles at notable companies such as Medivation, BeiGene, Sobi, Axovant Sciences, and Genentech/Roche, and has been involved in significant licensing and acquisition initiatives, including Medivation's $14 billion acquisition by Pfizer [4][5]. Strategic Focus - In her new role, Cantrell will lead the business development strategy, focusing on strategic partnerships, licensing opportunities, and corporate development initiatives to support the company's growth [3][4]. - The company aims to advance its mission of delivering a differentiated ophthalmic formulation of bevacizumab while maximizing long-term shareholder value [3].